Ductal Breast Carcinoma in Situ Clinical Trial
Official title:
Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial
Verified date | August 2019 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in reducing inflammatory changes in breast tissue in obese women at high risk for breast cancer. Curcumin may reduce inflammation in breast tissue and fat. This may affect the risk of developing breast cancer.
Status | Completed |
Enrollment | 29 |
Est. completion date | September 19, 2016 |
Est. primary completion date | September 19, 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 19 Years and older |
Eligibility |
INCLUSION CRITERIA: - Increased risk for breast cancer based on family history, personal history - Normal mammogram, clinical breast examination in the past 12 months - >1 year from pregnancy, lactation or chemotherapy - Body mass index (BMI) between 25 - 40 EXCLUSION CRITERIA: - Concurrent malignancy or metastatic malignancy of any kind - Ongoing chemotherapy, radiation therapy, or other cancer-related treatment - History of a bleeding tendency or current use of Coumadin or other anticoagulants - Current or previous history of liver, gastrointestinal, hematopoietic, cardiac or renal disease, viral, bacterial, atypical or fungal infections of any organ system and human immunodeficiency virus (HIV) infection - Pregnant or lactating women - Concurrent use of hormonal contraception or hormone replacement therapy - Concurrent use of immunosuppressant medications - Concurrent use of medications known to inhibit or induce hepatic enzyme cytochrome P450 (CYP) 3A4 - Barriers to fine needle aspiration sampling of breast adipose, including breast implants, history of radiation to both breasts, bilateral mastectomies, and/or insufficient breast adipose tissue for adequate fine needle aspiration (FNA) sampling - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements - Chronic use of any herbal or dietary supplement containing curcumin or curcuminoids within the 3 months prior to entry on the study or any other supplements that might interact with NEC - Known sensitivity or allergy to turmeric spices or curry - Dietary intake of large amounts of curry, turmeric spices or black pepper on a regular basis - Subjects on a standing regimen of full dose aspirin (>= 325 mg/day), non-steroidal anti-inflammatory drug (NSAID)s or NSAID-containing products |
Country | Name | City | State |
---|---|---|---|
United States | Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the adherence, tolerability and safety of two doses of nanoemulsion curcumin (NEC)in women at high risk for developing breast cancer. | Confidence interval estimates will be obtained from the repeated analysis of variance and two-sample t tests. | Up to 3 months | |
Secondary | Evaluate possible correlations between physical factors such as body mass (BMI), dietary intake and pro-inflammatory effects in plasma and breast adipose tissue. | up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02314156 -
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
|
Phase 2 | |
Completed |
NCT01874184 -
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT01905046 -
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
|
Phase 3 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT02587663 -
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
|
N/A | |
Active, not recruiting |
NCT04537312 -
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
|
N/A | |
Active, not recruiting |
NCT01245712 -
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02993159 -
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
|
Phase 2 | |
Completed |
NCT01753908 -
Broccoli Sprout Extract in Treating Patients With Breast Cancer
|
Early Phase 1 | |
Terminated |
NCT02023008 -
Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy
|
N/A | |
Terminated |
NCT01754519 -
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT01849250 -
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
|
Phase 2 | |
Completed |
NCT01819233 -
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT03077841 -
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02352883 -
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
|
N/A | |
Recruiting |
NCT03909282 -
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
|
N/A | |
Completed |
NCT01723943 -
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
|
N/A | |
Completed |
NCT00637481 -
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03391388 -
3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer
|
Phase 2 | |
Completed |
NCT02526498 -
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
|
Phase 2 |